At the time of writing, Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $52.99, up 8.12%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RYTM shares have gain 7.20% over the last week, with a monthly amount glided 6.77%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on October 21, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $70. Previously, H.C. Wainwright started tracking the stock with Buy rating on September 18, 2024, and set its price target to $64. On September 17, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $64 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $42 on May 08, 2024. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $55 on December 19, 2023. BofA Securities upgraded its rating to Buy for this stock on August 01, 2023, and upped its price target to $27.
For the past year, the stock price of Rhythm Pharmaceuticals Inc fluctuated between $23.26 and $55.64. Currently, Wall Street analysts expect the stock to reach $48.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $52.99 at the most recent close of the market. An investor can expect a potential drop of -8.28% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
According to Rhythm Pharmaceuticals Inc [NASDAQ:RYTM], the company’s sales were 101.78M for trailing twelve months, which represents an 51.28% jump. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.61%, Pretax Profit Margin comes in at -2.54%, and Net Profit Margin reading is -2.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -2.22 and Total Capital is -0.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 49.76 points at the first support level, and at 46.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.90, and for the 2nd resistance point, it is at 56.81.
Ratios To Look Out For
It is important to note that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] has a current ratio of 6.53. In addition, the Quick Ratio stands at 6.31 and the Cash Ratio stands at 2.95. Considering the valuation of this stock, the price to sales ratio is 32.68, the price to book ratio is 82.29.
Transactions by insiders
Recent insider trading involved GOOD JENNIFER L, Director, that happened on Sep 17 ’24 when 31751.0 shares were sold. Director, JENNIFER GOOD completed a deal on Sep 17 ’24 to buy 31751.0 shares. Meanwhile, Chief Human Resources Officer Cramer Pamela J. sold 4099.0 shares on Sep 09 ’24.
